vimarsana.com
Home
Live Updates
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update : vimarsana.com
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase
Related Keywords
United States ,
Australia ,
New York ,
American ,
Australian ,
Jonathan Finn ,
Tessa Cigler ,
Eric Van Zanten ,
Matthew Goetz ,
Development Expense ,
Atossa Therapeutics Inc ,
Weill Cornell Breast Center ,
Mayo Clinic Women Cancer Program ,
American Association For Cancer Research ,
Nasdaq ,
Mayo Clinic Comprehensive Cancer Center ,
Australian Taxation Office ,
Exchange Commission ,
Vantage Consulting Group ,
Endoxifen Clinical Trial ,
Re Evaluating Conditions ,
Active Surveillance Suitability ,
Ductal Carcinoma In Situ ,
Oestrogen Receptor ,
Human Epidermal Growth Factor Receptor ,
Endoxifen Versus ,
American Association ,
Cancer Research ,
Mayo Clinic Women ,
Executive Vice President ,
Chief Investment Officer ,
Steven Quay ,
Chief Executive ,
Year Ended December ,
Administrative Expense ,
Selective Estrogen Receptor Modulator ,
Private Securities Litigation Reform Act ,
Nasdaq Stock Market ,
Annual Reports ,
Quarterly Reports ,
vimarsana.com © 2020. All Rights Reserved.